Molecular mechanisms of tetrahydropyrrolo[1,2-c]pyrimidines as HBV capsid assembly inhibitors.
As an attractive therapeutic strategy for chronic hepatitis B virus (HBV), HBV capsid assembly inhibitors have got increased attention, which induce aberrant capsid assembly and thereby affect viral replication. In this work, molecular docking, molecular dynamics simulations, binding free energy calculations and per-residue energy decomposition were implemented to investigate the binding mechanism between tetrahydropyrrolopyrimidines scaffold inhibitors and HBV capsid protein. The obtained results displayed that the non-polar interaction, hydrogen bond interaction, polar interaction and π-π stacking interaction together help to stabilize the conformation of inhibitors in the interface of HBV core proteins, and residues Pro25, Thr33, Trp102, Ile105, Tyr118, Ile139, Leu140 (chain B), and Val124, Trp125, Thr128, Arg133 (chain C) were important participants during binding process. The replacement of the electronegative groups F, Cl and sulphonamide in inhibitor 28a would alter the major inhibitory effects of binding and activation. The models established by three-dimensional quantitative structure-activity relationship could be used to predict the anti-HBV activities of the tetrahydropyrrolopyrimidines molecules. This study will help understanding the molecular mechanisms and novel designed small molecules could act as better inhibitors.